DOI 10.1007/s00262-016-1909-3 REVIEW
Tumor‑directed immunotherapy can generate tumor‑specific T cell responses through localized co‑stimulation
Peter Ellmark
1,2· Sara M. Mangsbo
3· Christina Furebring
1· Per Norlén
1· Thomas H. Tötterman
3Received: 5 April 2016 / Accepted: 29 September 2016 / Published online: 6 October 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 FcɣR Fc gamma receptor
ICOS Inducible T cell co-stimulator irAE Immune-related adverse events LAG-3 Lymphocyte-activation gene 3 PD-1 Programmed cell death protein 1 PD-L1 Programmed death-ligand 1
TIM-3 T cell immunoglobulin and mucin-domain containing-3
Treg Regulatory T cells
VISTA V-domain immunoglobulin (Ig)-containing suppressor of T cell activation
Introduction
The groundbreaking results with CTLA-4 and PD-1/PD-L1 checkpoint blocking antibodies provide a solid foundation for the field of cancer immunotherapy to build on. The field is now geared toward identifying drug candidates that act complementary or synergistically with checkpoint inhibi- tors to enhance the response rates [1]. At the same time, treatments need to be safer in order to allow a broader use of cancer immunotherapy.
Tumor-directed immunotherapy is an approach to focus the immune activation to the most relevant part of the immune system (Fig. 1). This concept has also been termed in situ vaccination [2, 3]. The aim of tumor-directed immu- notherapy is to activate immune cells that have already homed to the tumor/local lymph node where tumor anti- gens are present, while minimizing irrelevant activation of the rest of the immune system. Preclinical data suggest that this can reduce immune-related adverse events (irAE).
A critical aspect of tumor-directed immunotherapy is that it must be able to generate a systemic anti-tumor response Abstract The most important goals for the field of
immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects.
One approach to achieve these goals is to use tumor- directed immunotherapy, i.e., to focus the immune acti- vation to the most relevant part of the immune system.
This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that can generate tumor-specific T cell responses through localized immune activation.
Keywords Immunotherapy · Tumor-directed immunotherapy · Cancer · Intratumoral · Bispecific antibody · Immuno-oncology
Abbreviations
AdCD40L Adenoviral vector expressing CD40 ligand Cmax Peak plasma concentration of a drug after
administration
* Peter Ellmark
pek@alligatorbioscience.com
1
Alligator Bioscience AB, Medicon Village, 223 63 Lund, Sweden
2
Department of Immunotechnology, Lund University, Lund, Sweden
3